Rare Diseases | LOTUS EDITIONS
On the Line: BioMarin Pharma's CEO Jean Jacques Bienaime
Jean-Jacques Bienaimé | Leadership Team - BioMarin
Jean Jacques Bienaime – North Bay Leadership Council
BioMarin Pharmaceutical buys Zacharon for $10 million - San Francisco Business Times
Jean-Jacques Bienaimé (76) – 1st Alumnus with the title of ESCP Doctor Honoris Causa – ESCP
J.P. Morgan Healthcare Conference
BioMarin Pharmaceutical 1Q loss rises amid higher expenses for product launch
BioMarin Pharmaceutical (NASDAQ: BMRN) wins FDA approval for $700,000 Batten disease drug Brineura - San Francisco Business Times
Jean Jacques Bienaime vs Heather Bresch | Comparably
BioMarin Pharmaceutical Inc - Jean-Jacques Bienaimé Chairman and Chief Executive Officer
BioMarin CEO Jean-Jacques Bienaimé - Xconomy
BioMarin was ranked fourth on the 2019 list of "America's Best Midsize Employers" by Forbe's magazine
Jean Jacques Bienaime Sells 1,500 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock - Opera News
BioMarin's CEO Bienaime, in his 16th year at the helm, scores $18M pay package | FiercePharma
jean-jacques-bienaime-biomarin-ceo | North Bay Life Science Alliance
Jean-Jacques Bienaime
The Rocky Journey To Refocusing BioMarin
Jennifer Bienaime with Jean-Jacques Bienaime
Jean-Jacques Bienaimé | Health Evolution
Jean-Jacques Bienaime Archives - Business & Finance | Business & Finance
Jean-Jacques Bienaimé (76) – 1st Alumnus with the title of ESCP Doctor Honoris Causa – ESCP
Jean-Jacques Bienaimé BioMarin | The CEO Magazine
Jennifer Bienaime with Jean-Jacques Bienaime
People | Nature Biotechnology
